| Medical and Health Sciences | Lifetime | 597 | JP 3 | 99.97 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 51 | JP 1 | 99.82 |
| Molecular Biology | Lifetime | 593 | JP 14 | 99.71 |
| Epidemiology | Lifetime | 311 | JP 8 | 99.61 |
| Surgery | Lifetime | 777 | JP 22 | 99.28 |
| Medical Physiology | Lifetime | 635 | JP 2 | 98.91 |
| Clinical Pharmacology | Lifetime | 874 | JP 23 | 95.92 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 80 | JP 1 | 98.88 |
| Epidemiology | 2021-2025 | 800 | JP 20 | 92.15 |
| Medical Physiology | 2021-2025 | 686 | JP 12 | 89.11 |
| Genetics | 2021-2025 | 670 | JP 11 | 79.70 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 13 | JP 2 | 99.91 |
| Adipose Tissue and Metabolism | Lifetime | 34 | JP 2 | 99.84 |
| Metabolism, Diabetes, and Cancer | Lifetime | 15 | JP 1 | 99.87 |
| Pancreatic function and diabetes | Lifetime | 39 | JP 1 | 99.79 |
| Diabetes Treatment and Management | Lifetime | 31 | JP 1 | 99.82 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 31 | JP 1 | 99.52 |
| Diabetes Management and Research | Lifetime | 101 | JP 1 | 99.52 |
| Cardiovascular Disease and Adiposity | Lifetime | 165 | JP 7 | 99.08 |
| Regulation of Appetite and Obesity | Lifetime | 128 | JP 7 | 98.98 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 212 | JP 2 | 99.18 |
| Diabetes and associated disorders | Lifetime | 285 | JP 5 | 98.65 |
| Pharmacology and Obesity Treatment | Lifetime | 91 | JP 1 | 98.74 |
| Diabetes Management and Education | Lifetime | 340 | JP 3 | 96.67 |
| Growth Hormone and Insulin-like Growth Factors | Lifetime | 871 | JP 20 | 96.47 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 810 | JP 71 | 95.09 |
| Lipid metabolism and disorders | Lifetime | 824 | JP 50 | 92.47 |
| Potassium and Related Disorders | Lifetime | 844 | JP 29 | 86.58 |
| Biomarkers in Disease Mechanisms | Lifetime | 841 | JP 63 | 80.84 |
| Diabetes Treatment and Management | 2021-2025 | 122 | JP 2 | 98.63 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 62 | JP 1 | 97.88 |
| Diabetes Management and Research | 2021-2025 | 285 | JP 3 | 96.47 |
| Pharmacology and Obesity Treatment | 2021-2025 | 97 | JP 1 | 92.24 |
| Pancreatic function and diabetes | 2021-2025 | 920 | JP 31 | 87.35 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 831 | JP 44 | 84.70 |
| Diabetes Management and Education | 2021-2025 | 780 | JP 8 | 75.88 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 211 | JP 13 | 73.75 |
| Potassium and Related Disorders | 2021-2025 | 612 | JP 53 | 63.89 |